In a letter on Tuesday to Eli Lilly CEO David Ricks, Sen. Ruben Gallego (D-AZ) said the company needs to explain the details of its deal with the Trump administration over its weight loss drugs ... Read more
Endpoints News - Nov 18
In a major new study, researchers from Intermountain Health in Salt Lake City have found that weight loss drugs used by patients who have high triglycerides do not increase their risk of pancreatitis or adverse cardiac events. Read more
Medical Xpress - Nov 09
Certain GLP-1 weight loss medications will be available for as little as $149 per month, a sharp drop from the current average retail price of $1,000–$1,350. Read more
International Business Times - Nov 07
Jared Holz, Mizuho Securities health care strategist, joins 'Power Lunch' to discuss the latest announcement from the White House, the balance between prices and much more. Read more
Cnbc - Nov 06
"The ultimate defence in our industry is in innovation," Knudsen told Fortune in an exclusive interview. Read more
Fortune - Nov 06
Jeffrey Finer, CEO of Septerna, discusses the company's phase-one clinical trials and its goal of turning injectable medications into oral pills. Read more
Cnbc - Oct 31
There are now 7.6 million fewer American adults living with obesity Read more
The Independent - Oct 29
For the first time in over a decade, obesity rates in the US are down, from 39% to 37.7%. Read more
Abc 30 - Oct 29
A real weight loss drug, called retatrutide, is currently being developed by pharmaceutical giant Eli Lilly, but there has been worrying content online promoting a fake version, which could be 'dangerous' Read more
Mirror - Oct 18
